ClinicalTrials.gg
RecruitingNCT07031713Updated Nov 24, 2025

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

A Phase 1 interventional study of CAR-T Therapy in Systemic Lupus Erythematosus (SLE), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Planned enrollment
6th of 11
12 · median 12
Started
2025
with 2 others
Phase 1
7 of 11
5 open now
Registered
6th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 7 in phase 1, and was the 6th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, or all of them as a file.
02

Study summary

A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus.

This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabolic dynamics of ct1192 cells in patients with SLE.

Read the detailed description

The study was divided into dose increasing stage and dose expanding stage. dose escalation phase Three dose levels are tentatively determined for dose escalation: 3.0 × 108, 4.5 × 108 and 6.0 × 108 car-cd19/CD20+T cells. It is estimated that the target toxicity probability of the maximum tolerated dose is 30%, and about 12 participants are planned to be enrolled, and the number of enrolled patients in each dose group is subject to the actual situation. During the test, the researchers and partners will jointly negotiate whether to increase or decrease the dose, whether to increase to the set maximum dose group or produce the maximum available cell volume, and whether to increase the exploration of new dose level within the explored dose range (allowed to be conducted when the dose is increased or decreased) according to the participants' cell metabolism characteristics, safety, tolerance and preliminary effectiveness data, so as to determine the possible recommended therapeutic dose (RD).

The DLT observation period is 28 days after the first infusion. If the treatment needs to be withdrawn before 28 days after the infusion due to disease progression or other reasons, no obvious car-t cell expansion is detected or car-t treatment is invalid, and the DLT related AE events determined by the researcher may not be related to the product, the DLT observation period can be completed before. During each dose increase, if there is a safety risk that needs to be discussed, the researchers and partners can make a dose increase/stability/decrease decision according to the safety and tolerance of participants and the metabolic kinetics of ct1192 cells. In the same dose group, the first participant had no significant safety risk 14 days after the completion of cell infusion, and subsequent participants could only carry out cell infusion.

dose expansion phase One or more dose groups may be selected for dose expansion according to the results of the dose increasing stage to further explore the efficacy and safety in SLE patients. Each dose group and each queue plan to include up to 9 cases, and the specific number of patients in the group is subject to the actual number. DLT will not be observed in the dose expansion phase, and other research processes are the same as the dose increment phase. Researchers and collaborators will continue to monitor the safety data of the whole dose expansion phase and make decisions on admission and exit when necessary.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the EULAR/ACR 2019 SLE classification criteria, with a medical history of ≥ 6 months;
  2. Voluntarily sign the Form (ICF); When signing the ICF, the age range is between 18 and 60 years old (including 18 and 60 years old), with no gender restrictions;
  3. No systemic active infections (such as infectious pneumonia or tuberculosis) within the first 2 weeks of screening;
  4. Women with fertility (defined as all physiologically capable women) must agree to use effective methods from at least 28 days prior to the start of vaginal discharge until 1 year after CT1192 infusion. Egg donation is strictly prohibited within 1 year after receiving the study treatment infusion during the study period. Male partners with fertility must agree to use effective barrier contraception methods from the start of vaginal discharge until 1 year after CT1192 infusion, and should not donate semen or sperm throughout the entire study period;
  5. Women with fertility must have a negative serum β - human chorionic gonadotropin (β - hCG) test result within 48 hours prior to screening and gonorrhea treatment.
  6. Prior to screening, patients must have received a combination of and (including cyclophosphamide, mycophenolate mofetil, tacrolimus, methotrexate, cyclosporine, leflunomide) and/or biologics for at least 3 months, with a stable dose for at least 2 weeks and the disease still active. During screening, oral steroids must meet the following requirements:

If hormone therapy is used alone, prednisone (or equivalent medication) should be ≥ 7.5 mg/day; When used in combination with immunosuppressants and/or biologics, there is no minimum daily dose requirement for hormones; 7. Positive for anti nuclear antibodies, anti ds DNA antibodies, and/or anti Smith antibodies during screening; 8. During the screening period, if the SLEDAI-2K score is ≥ 7 points, or if there is significant organ dysfunction, such as severe immune thrombocytopenia or lupus nephritis ( diagnosed as active nephritis type III or IV with or without type V); 9. Active organ involvement during screening (including kidneys, heart and lungs, musculoskeletal system, blood system, blood vessels, etc.; skin and mucosal involvement alone cannot be included); 10. Adequate organ function:

  1. Renal function: defined as a rate (Cockcroft Gault) calculated without hydration assistance of ≥ 50 mL/min;
  2. Bone marrow function: defined as (ANC) ≥ 1.0 × 109/L and (Hb) ≥ 60 g/L. Blood transfusions and growth factors must not be used to meet these requirements within 7 days prior to eligibility screening;
  3. Liver function: defined as (ALT) and aspartate aminotransferase (AST) ≤ 2 x (ULN), total ≤ 2 x upper limit of normal (ULN)
  4. Coagulation function: defined as (INR) or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN;
  5. Pulmonary function: Blood oxygen saturation (SpO2) ≥ 92% in indoor air (measured by pulse oximeter);
  6. Cardiac function: defined as a (LVEF) of ≥ 50% evaluated by echocardiography (ECHO) within the first 8 weeks of screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe lupus nephritis within the first 2 months of screening need to undergo hemodialysis or receive prednisone ≥ 100 mg/d or equivalent hormone therapy for ≥ 14 days;
  2. Have undergone plasma exchange, plasma separation, hemodialysis within 30 days prior to screening, or have had lupus crisis within 30 days prior to screening;
  3. Individuals with a history of ≥ grade 2 bleeding or requiring long-term anticoagulant therapy within the 30 days prior to screening;
  4. Screening for a history of any of the following cardiovascular diseases within the previous 30 days: Grade III or IV heart failure defined by the (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other heart diseases;
  5. Prior to screening, central nervous system manifestations caused by lupus, including but not limited to lupus headache, epileptic seizures, cognitive impairment, impaired intellectual function, visual impairment, etc;
  6. Individuals with central nervous system diseases prior to screening include but are not limited to: cerebrovascular accidents, encephalitis, epilepsy, seizures/convulsions, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar diseases, central nervous system vasculitis, cognitive dysfunction, organic brain syndrome, or psychiatric disorders;
  7. No systemic active infections, including but not limited to active tuberculosis, within 2 weeks prior to screening;
  8. Previously received CAR-T cell or other genetically modified T cell therapy, or have a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation;
  9. Allergic or intolerant reactions to Qinglin drugs, tocilizumab, or life-threatening allergic reactions, reactions, or intolerance to CT1192 preparations or their (including dimethyl sulfoxide (DMSO)), or previous history of other severe allergies such as anaphylactic shock;
  10. Screening for drugs targeting B cells, such as rituximab, that have been used within the previous 6 months;
  11. Within the 12 weeks prior to screening, other biologics such as taceptil and belimumab have been used for treatment;
  12. Hormone use ≥ 10 mg/day of prednisone (or equivalent) within 2 weeks prior to CT1192 infusion, with the use of physiological substitutes, topical and inhaled allowed;
  13. Received agents that affect T cells (mycophenolate mofetil, methotrexate, cyclosporine, azathioprine, leflunomide, tacrolimus) within 2 weeks prior to CT1192 infusion;
  14. Have received JAK inhibitors (tofacitinib, baritinib tablets, lukatinib, etc.) within 2 weeks prior to CT1192 infusion;
  15. Have received attenuated , inactivated vaccine or RNA vaccine within one month before screening;
  16. Suffering from malignant tumors within 2 years prior to signing the ICF. Except for the following situations: non melanoma skin cancer that has undergone radical treatment, local prostate cancer, cervical carcinoma in situ confirmed by or squamous intraepithelial lesions detected by cervical smear, and breast carcinoma in situ that has been completely removed;
  17. If a major surgery has been performed within 4 weeks prior to signing the form, or if a major surgery is planned during the study period, the researcher believes that it would pose unacceptable risks to the participants; During screening, there may be , syphilis infection, active virus infection (HBsAg positive and HBV-DNA above the detection limit), or active virus infection (HCV antibody and HCV-RNA positive);

19. Participate in other clinical studies within the first 3 months of screening or still within the five half lives after the last medication; 20. Merge major chronic diseases that have not been controlled and researchers believe may increase the risk for participants; 21. If there is a history or evidence of suicidal thoughts within the previous 6 months, or any suicidal behavior within the previous 12 months, the researcher believes that there is a significant risk of suicide; 22. Pregnant or lactating women; According to the researcher's assessment, participants have poor compliance, are unable or unwilling to comply with the requirements of the research protocol, or are not suitable to participate in this clinical study for other reasons.

5.5 Pre cleaning standard Before clearing, the following assessment needs to be completed. If the participant meets the following criteria, clearing can be performed. Otherwise, clearing cannot be performed or may need to be delayed.

  1. Not using immunosuppressants in the week before Qinglin treatment;
  2. Female participants with fertility potential who undergo pregnancy studies within 24 hours prior to the clearance of gonorrhea and have negative results;
  3. Blood oxygen saturation ≥ 92% (under non auxiliary oxygen supply conditions);
  4. Inactive or uncontrollable systemic infection; The use of anti infective drugs within 7 days before clearing gonorrhea must be reviewed by a medical inspector;
  5. No signs of CNS disease or abnormal neurological examination results with clinical significance;
  6. Serious abnormalities in heart, lung, liver, kidney function, and endocrine disorders, including but not limited to: newly developed arrhythmias or heart failure that cannot be controlled by medication; Hypotension requiring the use of vasopressors; Bacterial, fungal, or viral infections with increased activity/progression determined by researchers;
  7. Researchers assess that participants are unable to comply with the requirements of the study protocol or are not suitable to continue the study in other situations.

If a participant shows obvious abnormalities such as symptoms, signs, or test results during or after clearing the lymphatic system, the researcher must communicate with the cooperating medical monitor to discuss whether the participant is suitable to continue receiving CT1192 cell infusion.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CT1192 CAR-T cells Injection

    CT1192 cells infusion

    Biological: CAR-T Therapy

Interventions

  • BiologicalCAR-T Therapy

    CT1192 cells infusion

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of ct1192 in participants with moderate to severe refractory SLE

    The incidence and severity of dose limiting toxicity (DLT), adverse events (AE), serious adverse events (SAE), and AESI (adverse events of particular concern)

    Time frame: Within 28 days after infusion for DLT, within 180 days after infusion fOr AE/SAEwithin 12 months after infusion for AESl

  2. Evaluate the maximum tolerable dose (MTD) and/or dose range of ct1192

    Ct1192 MTD and/or dose range

    Time frame: After medication to day 28

Secondary outcomes

  1. Proportion of participants with SLE responder index (sri-4)

    Preliminary evaluation of the efficacy of ct1192 in the treatment of moderate to severe refractory SLE.Proportion of participants who reached SLE responder index (sri-4) at 6 months and other time points (1, 3, 9 and 12 months after medication)

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  2. Proportion of participants with low lupus disease activity status (lldas)

    To evaluate the efficacy of ct1192 in the treatment of moderate to severe refractory SLE. The proportion of participants who reached lupus low disease activity status (lldas) at 6 months and other time points (1, 3, 9 and 12 months after medication).

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  3. Proportion of participants achieving disease remission (doris)

    To evaluate the efficacy of ct1192 in the treatment of moderate to severe refractory SLE. The proportion of participants who achieved disease remission (doris) at 6 months and other time points (1, 3, 9 and 12 months after medication).

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  4. Changes of SLE disease activity index (sledai-2k) score from baseline after medication

    To evaluate the efficacy of ct1192 in the treatment of moderate to severe refractory SLE. The SLE disease activity index (sledai-2k) scores at 6 months and other time points (1, 3, 9 and 12 months) after treatment were changed from baseline.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  5. After treatment, the SLE disease activity index (Selena - SLEDAI) score changed from baseline

    To evaluate the efficacy of ct1192 in the treatment of moderate to severe refractory SLE. The SLE disease activity index (Selena - SLEDAI) scores at 6 months and other time points (1, 3, 9 and 12 months) after treatment were changed from baseline.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  6. After treatment, the index of lupus erythematosus assessment group (bilag-2004) changed from baseline

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. Changes in the British Islet Lupus Assessment Group Index (BILAG-2004) compared to baseline at 6 months and other time points (1, 3, 9, and 12 months) after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  7. The SLE activity score (sle-das) changed from baseline after treatment

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. Changes in SLE Disease Activity Score (SLE-DAS) compared to baseline at 6 months and other time points (1, 3, 9, and 12 months) after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  8. Changes in clinicians' overall judgment (PGA) score from baseline after medication

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. The overall assessment (PGA) score of clinical physicians changed from baseline at 6 months and other time points (1, 3, 9, and 12 months) after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  9. Proportion of patients without other SLE therapy after medication

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. The proportion of patients without other SLE therapies at 1, 3, 6, 9, and 12 months after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  10. Changes in immunoglobulin (IgG, IgM, IgA) levels during medication

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. Changes in immunoglobulin (IgG, IgM, IgA) levels at 1, 3, 6, 9, and 12 months after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  11. The changes of serum markers (anti DS DNA antibody, anti Smith antibody, antinuclear antibody Ana, complement C3) of SLE after treatment

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. Changes in serum markers of SLE disease (anti ds DNA antibody, anti Smith antibody, anti nuclear antibody ANA, complement C3) levels at 1, 3, 6, 9, and 12 months after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  12. The change value of post medication Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline

    Preliminary evaluation of the effectiveness of CT1192 for moderate to severe refractory SLE. Changes in Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline at 1, 3, 6, 9, and 12 months after medication.

    Time frame: 1, 3, 6, 9 and 12 months after drug use

  13. Copy number and duration of ct1192 gene in blood

    Objective to evaluate the cell kinetics of ct1192 in SLE participants, and to observe the level and duration of ct1192 gene copy number in blood.

    Time frame: Within 1 year after CAR-T cell infusion

  14. Changes of B cell functional subsets (initial B cells, memory B cells, plasma cells) after ct1192 infusion

    Evaluate the efficacy (PD) characteristics of CT1192 in SLE participants. Changes in the levels of B cell functional subgroups (initial B cells, memory B cells, plasma cells) after CT1192 infusion.

    Time frame: Within 1 year after CAR-T cell infusion

  15. Changes in cytokine levels after CT1192 infusion

    Evaluate the efficacy (PD) characteristics of CT1192 in SLE participants. Changes in cytokine levels after CT1192 infusion.

    Time frame: Within 1 year after CAR-T cell infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 22, 2025
StartActual
Jul 11, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07031713
Collaborators
CARsgen Therapeutics Co., Ltd.
Responsible party
Qiubai Li (Director, Head of Department of Rheumatology and Immunology, Principal Investigator, Professor, Wuhan Union Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Jun 22, 2025
Start date
Jul 11, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 24, 2025

Study contacts

Qiubai Li
Contact
qiubaili@hust.edu.cn
Professor 85726808 Ext.027

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion